Accès ouvert
2026
article
OpenAlex
Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, Marco Maruzzo et autres
Background: Avelumab maintenance therapy is an established therapeutic approach for patients with advanced urothelial carcinoma (UC) whose disease has not progressed after first-line platinum-based chemotherapy. However, evidence on its effectiveness and safety in elderly patients remains limited. Methods: This multicenter retro-prospective Italian …
it, ch, my
(code pays fourni par la source)
2026
article
OpenAlex
John V. Heymach, Geoffrey Liu, Ligang Xing, Laurent Greillier et autres
LBA8500 Background: Sunvozertinib has been granted accelerated approval in the US and China for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) who failed platinum-based chemotherapy, based on …
us, ca, cn, fr, au, tr, pl, it, es
(code pays fourni par la source)
2026
article
OpenAlex
Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John et autres
BACKGROUND: ) exon 20 insertion mutations. Data are needed on the efficacy and safety of sunvozertinib as a first-line treatment for NSCLC. METHODS: exon 20 insertions to receive sunvozertinib or chemotherapy (carboplatin-pemetrexed). The primary end point was progression-free survival as assessed by …
cn, fr, ca, au, pl, us, tr, es, it, br
(code pays fourni par la source)
2026
article
OpenAlex
Giulia Massaro, Giulia Petroni, Daniele Lavacchi, Daniele Rossini et autres
e16189 Background: Predictive and prognostic factors in advanced CCA remain limited. Although obesity is a recognized risk factor, an “obesity paradox” with improved outcomes in overweight patients (pts) has been reported in several solid tumors. In addition, sex-related differences in immune responses …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Kanwal Pratap Singh Raghav, Hideaki Bando, Tao-Wei Ke, Meredith Pelster et autres
TPS3688 Background: Curative intent standard of care (SOC) management of colorectal cancer (CRC) involves surgical tumor removal, followed by adjuvant therapy and active surveillance (AS). Presence of circulating tumor DNA (ctDNA) in the absence of radiographic evidence of disease is emerging as …
us, jp, tw, it, dk, kr
(code pays fourni par la source)
2026
article
OpenAlex
Giuseppe Maglietta, Angela Damato, Francesca Spada, Francesco Iachetta et autres
e14572 Background: EPSCC is a rare and highly aggressive malignancy with a poor prognosis. The low incidence has limited prospective evidence for first-line (1L) treatment. Given histological similarities with small cell lung cancer, where immunotherapy plus chemotherapy (CT) is the standard of …
it
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Roberta Renda, Cecilia Cerbai, Francesca Castiglione, Maria Cristina Petrella et autres
e17579 Background: Platinum-resistant ovarian cancer (PROC) has limited treatment options, with response rates of 10–15% and median progression-free survival (PFS) of ~ 3.5 months. Mirvetuximab soravtansine (MIRVE), a folate receptor alpha (FRα-)directed antibody-drug conjugate, is the first targeted therapy approved for FRα-positive …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Martina Carullo, Carlotta Antoniotti, Zhong Wee Poh, Veronica Conca et autres
3570 Background: ICIs provide limited benefit in proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), highlighting the need for predictive biomarkers. We aimed to uncover transcriptomic profiles predictive of ICI efficacy, using tumor specimens from two matched cohorts of pMMR, RAS/BRAF wild-type …
it, sg
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Giovanni Trovato, Daniele Rossini, Paolo Ciracì, Chiara Cavalli et autres
3581 Background: The SUNLIGHT trial established FTD/TPI+Bev as a preferred 3rd-line option for unselected mCRC patients (pts). Recently, the phase II randomized PARERE trial reported high response rates and favorable progression-free survival (PFS) with anti-EGFR re-treatment in RAS/BRAF wild-type (wt) mCRC pts …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Costanza Winchler, Fabio Marra, Alfredo Vozza, Daniele Rossini et autres
4117 Background: Immune checkpoint inhibitor–based combinations (ICIs), including atezolizumab–bevacizumab (AB), have dramatically changed the therapeutic landscape of unresectable hepatocellular carcinoma (HCC), improving survival and response rates of patients, although outcomes remain heterogeneous. Concomitant medications may modulate immunotherapy efficacy through systemic and tumor …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Martina Cassaniti, Alessandra Boccaccino, Daniele Rossini, Lisa Salvatore et autres
3539 Background: dMMR/MSI-H metastatic colorectal cancer (mCRC) is more common among the elderly. However, insufficient data about their treatment with immune checkpoint inhibitors (ICIs) are available from interventional and observational trials. Methods: ELDER CRC is an observational, multicenter Italian trial enrolling elderly …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Petros Grivas, Begoña P. Valderrama, Marinos Tsiatas, Peter Mu-Hsin Chang et autres
4568 Background: Ave 1L maintenance is a recommended treatment option for patients (pts) with aUC without progression after 1L platinum-based chemotherapy (PBC). In the JAVELIN Bladder Medley phase 2 trial (NCT05327530), 1L maintenance with Ave + SG (Trop-2–directed antibody-drug conjugate) improved progression-free …
us, es, gr, tw, kr, it, de, ca
(code pays fourni par la source)